1/ This scandal—misuse of the diagnosis 'schizophrenia' to hide the use of high-risk drugs in the elderly—is a crisis for psychiatry. We need to speak out—and demand the disciplining of doctors who misdiagnose to hide understaffing. nytimes.com/2021/09/11/hea…
2/ That said, the scandal appears to arise from well-intentioned policy-making. You don't want to punish nursing homes that admit residents with mental illnesses or neurological disorders. Changing the metrics will only risk further unintended problems.
3/ Perhaps misdiagnosis should itself be a metric so that nursing homes that engage in it are downgraded and punished. (No institution should see a lot of schizophrenia that emerges in late life.) That move would require further expert oversight, to pre-COVID levels and beyond.
4/ Kudos to @nytimes for the exposé. Outstanding reporting—and please don't let the issue fade away.
Drugs and diagnoses are being misused, families are being mislead, corrupt nursing homes & professionals are flourishing, and people are dying—losing months & years of life.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
@NYTObits writes of John Gunderson: "He was adamant over the years that psychiatric drugs did not help resolve #borderline symptoms." nyti.ms/2E6UmHv This statement is narrowly true. In lectures, he specified circumstances that warrant the use of a range of medications...
6 months ago, while arguing against widespread use of lamotrigine in #BPD, Gunderson wrote, "Clinical experience has shown that medications can help build an alliance, can relieve states of distress, and can sometimes be helpful for comorbid disorders." ajp.psychiatryonline.org/doi/10.1176/ap…
He spoke of instances when mood stabilizers, #SSRIs, and even antipsychotics might be of use. He spoke out against the overuse of medication but saw a role for judicious use in clinical management. ucdenver.edu/academics/coll…
1/ Thread: New study forthcoming on whether #gene-testing can help guide #antidepressant selection for #depressed patients who have failed to respond to 1 or (on average) 3-4 trials of medication. bit.ly/2LQU75I I have been skeptical: mostly, scant added value…
2/ & I found the reporting of this study annoying. On the primary endpoint, improvement in average #depression rating scores, the gene-testing failed. Patients whose MDs chose new meds w/o help of gene tests did just as well—& yet news reports suggested that tests can help…
3/ That's because the gene testing led to a choice of new meds that led to significantly more remissions (patient no longer depressed) and responses (halving of symptom burden). In general, in drug trials, response/remission shows antidepressants to better effect…
1/ Important study on #antidepressants & #heartdisease. 6 months of Rx for even minor depression in #cardiac patients offers protection against adverse events (heart attack, death, etc) seen for many (8+) years out. bit.ly/2LBZPuM@JAMA_current # of interesting points...
2/ The effects of meds on mood were the same as those in many other studies, 2-3 points difference on symptoms, NNT to remission between 5 & 6, effect size under .4 …& this difference, often dismissed as minor, was associated with marked benefits in terms of overall health...
3/ it looks as if treating about 10 patients early on prevents one heart attack, w & other benefits for heart (& overall) health. Benefits were larger in those whose mood disorder remitted & those who completed the trial. So: good news. Brief inexpensive Rx w lasting benefits...